Abstract
In Plasmodium falciparum the biosynthesis of isoprenoids is achieved by the mevalonate-independent 1-deoxy-D-xylulose 5- phosphate (DOXP) pathway. The enzymes of the DOXP pathway are localised inside the plastid-like organelle (apicoplast). Fosmidomycin inhibits DOXP reductoisomerase, the second enzyme of this pathway. The antimalarial activity of fosmidomycin was established in vitro and in a rodent malaria model. Fosmidomycin alone or in combination with clindamycin was evaluated for the treatment of acute uncomplicated P. falciparum malaria in early phase II studies. Fosmidomycin monotherapy led to a fast parasite and fever clearance but was inefficient in radical elimination of the parasites. With the fosmidomycin-clindamycin combinations the cure ratio on day 28 was 100 % (10/10) with treatment durations of 5 and 4 days. The cure ratio was 90 % (9/10) with treatment duration of 3 days.
Keywords: Malaria, apicoplast, isoprenoid biosynthesis, DOXP reductoisomerase, fosmidomycin, FR900098
Current Drug Targets
Title: Isoprenoid Biosynthesis of the Apicoplast as Drug Target
Volume: 8 Issue: 1
Author(s): Jochen Wiesner and Hassan Jomaa
Affiliation:
Keywords: Malaria, apicoplast, isoprenoid biosynthesis, DOXP reductoisomerase, fosmidomycin, FR900098
Abstract: In Plasmodium falciparum the biosynthesis of isoprenoids is achieved by the mevalonate-independent 1-deoxy-D-xylulose 5- phosphate (DOXP) pathway. The enzymes of the DOXP pathway are localised inside the plastid-like organelle (apicoplast). Fosmidomycin inhibits DOXP reductoisomerase, the second enzyme of this pathway. The antimalarial activity of fosmidomycin was established in vitro and in a rodent malaria model. Fosmidomycin alone or in combination with clindamycin was evaluated for the treatment of acute uncomplicated P. falciparum malaria in early phase II studies. Fosmidomycin monotherapy led to a fast parasite and fever clearance but was inefficient in radical elimination of the parasites. With the fosmidomycin-clindamycin combinations the cure ratio on day 28 was 100 % (10/10) with treatment durations of 5 and 4 days. The cure ratio was 90 % (9/10) with treatment duration of 3 days.
Export Options
About this article
Cite this article as:
Wiesner Jochen and Jomaa Hassan, Isoprenoid Biosynthesis of the Apicoplast as Drug Target, Current Drug Targets 2007; 8 (1) . https://dx.doi.org/10.2174/138945007779315551
DOI https://dx.doi.org/10.2174/138945007779315551 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science The Cell-Wall Core of Mycobacterium tuberculosis in the Context of Drug Discovery.
Current Topics in Medicinal Chemistry Comprehensive Review and Comparison of Anticancer Peptides Identification Models
Current Protein & Peptide Science Antitubercular Natural Terpenoids: Recent Developments and Syntheses
Current Organic Synthesis Toll-Like Receptors: Role in Inflammation and Commensal Bacteria
Inflammation & Allergy - Drug Targets (Discontinued) Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Is There a Role for Antioxidants in the Prevention of Infection-Associated Carcinogenesis and in the Treatment of Infection-Driven Tumors?
Current Topics in Medicinal Chemistry Recent Studies of Antioxidant Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Anti-Infective Drug Discovery Bone Marrow Aspiration/Biopsy in the Evaluation of Fever of Unknown Origin in Patients with AIDS
Infectious Disorders - Drug Targets Comparison of Large Proteomic Datasets
Current Proteomics Intraocular Inflammation and Systemic Immune-Mediated Diseases
Current Immunology Reviews (Discontinued) A Randomized, Single Centered, Parallel and Open Labelled Interventional Study on Effectiveness of Clinical Pharmacists on Adverse Event Following Immunization (AEFI) in Pediatric Population
Current Drug Safety New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Sequence-Structure Similarity: Do Sequentially Identical Peptide Fragments have Similar Three-Dimensional Structures?
Current Bioinformatics Antimicrobial Peptide Precursor Structures Suggest Effective Production Strategies
Recent Patents on Inflammation & Allergy Drug Discovery Comprehensive Evaluation and Clinical Application of Combined Redox Assay Methods to Determine Total Antioxidant Capacity
Current Analytical Chemistry Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization
Current Pharmaceutical Design The Potential of Ganoderma Lucidum as Antimicrobial Agent for Multidrug- Resistant Mycobacterium Tuberculosis
Anti-Infective Agents